Overview
- The peer‑reviewed study published in May 2026 reported that mice treated with the three‑layer NanoMesh survived about twice as long as untreated controls and that 40% remained alive past the 120‑day end of the experiment.
- The implant embeds temozolomide, acriflavine and PT2385 and the research team found the three drugs worked synergistically, producing stronger anti‑tumor effects together than any single drug alone.
- Researchers made the mesh by electrospinning multilayer polymer fibers so they can control how much drug is loaded, the timing of release and the shape of the implant to target the surgical cavity.
- The work is at a preclinical stage with NIH support, and investigators are now optimizing long‑term release profiles, implant geometry and safety testing as steps toward larger‑animal studies and human trials.
- If translated to people, the platform could raise drug levels at tumor sites while reducing systemic side effects and it may be adaptable to other hard‑to‑treat diseases, but further testing is required before clinical use.